controllability, catastrophic potential, and equity into the risk-benefit equation. The impacts of public perceptions of risk cannot be lessened without drastic, politically unacceptable changes in the structure of our society. Thus, we must learn to treat perceptions as legitimate. We must attempt to understand them and to incorporate public concerns and wisdom into decision making, along with the wisdom gleaned from scientific assessments of risk.

Hall, S. 1987. One potato patch that is making genetic history. Smithsonian 18(5):125-136.

Kasperson, R. E., O. Renn, P. Slovic, H. S. Brown, J. Emel, R. Goble, J. X. Kasperson, and S. Ratick. 1988. The social amplification of risk: A conceptual framework. Risk Analysis 8:177-187.

Lichentenstein, S., P. Slovic, B. Fischoff, M. Layman, and B. Combs. 1978. Judged frequency of lethal events. Journal of Experimental Psychology: Human Learning and Memory 4:551-578.

Slovic, P. 1987. Perception of risk. Science 236:280-285.

Tversky, A., and D. Kahneman. 1973. Availability: A heuristic for judging frequency and probability. Cognitive Psychology 5:207-232.

Weinberg, A. M. 1976. The maturity and future of nuclear energy. American Scientist 64:16-21.

Zilinskas, R. A., and B. K. Zimmerman, eds. 1986. The Gene-Splicing Wars: Reflections on the Recombinant DNA Controversy New York: MacMillan.

Zinder, N. D. 1986. A personal view of the media's role in the recombinant DNA war. In The Gene-Splicing Wars: Reflections on the Recombinant DNA Controversy R. A. Zilinskas and B. K. Zimmerman, eds. New York: MacMillan.

Front Matter (R1-R8)

Introduction (1-8)

Unproven AIDS Therapies: he Food and Drug Administration and ddI (9-42)

A Political History of RU-486 (43-98)

The Human Genome Project: The Formation of Federal Policies in the United States, 1986-1990 (99-175)

Origins of the Medicare Kidney Disease Entitlement: The Societal Security Amendments of 1972 (176-214)

Deliberations of the Human Fetal Tissue Transplantation Research Panel (215-257)

Asilomar and Recombinant DNA: The End of the Beginning (258-307)

Conclusions (308-322)

Appendix A: The Public and the Expert in Biomedical Policy Controversies (323-331)

Appendix B: Biographical Notes on the Authors and Commentators (332-338)

Index (339-352)